These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 11245419

  • 1. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
    Suzuki S, Tadakuma T, Asano T, Hayakawa M.
    Cancer Res; 2001 Feb 15; 61(4):1276-9. PubMed ID: 11245419
    [Abstract] [Full Text] [Related]

  • 2. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP, Searle PF, Mautner V, James ND.
    Cancer Res; 2000 Jan 15; 60(2):334-41. PubMed ID: 10667585
    [Abstract] [Full Text] [Related]

  • 3. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
    Li Y, McCadden J, Ferrer F, Kruszewski M, Carducci M, Simons J, Rodriguez R.
    Cancer Res; 2002 May 01; 62(9):2576-82. PubMed ID: 11980652
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC.
    Cancer Res; 1999 May 01; 59(9):2136-41. PubMed ID: 10232600
    [Abstract] [Full Text] [Related]

  • 5. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW.
    J Urol; 1998 Jul 01; 160(1):220-9. PubMed ID: 9628654
    [Abstract] [Full Text] [Related]

  • 6. Human prostate cancer progression models and therapeutic intervention.
    Chung LW, Kao C, Sikes RA, Zhau HE.
    Hinyokika Kiyo; 1997 Nov 01; 43(11):815-20. PubMed ID: 9436028
    [Abstract] [Full Text] [Related]

  • 7. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
    Lee SE, Jin RJ, Lee SG, Yoon SJ, Park MS, Heo DS, Choi H.
    Anticancer Res; 2000 Nov 01; 20(1A):417-22. PubMed ID: 10769689
    [Abstract] [Full Text] [Related]

  • 8. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen.
    Pang S, Dannull J, Kaboo R, Xie Y, Tso CL, Michel K, deKernion JB, Belldegrun AS.
    Cancer Res; 1997 Feb 01; 57(3):495-9. PubMed ID: 9012480
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
    Petrigliano FA, Virk MS, Liu N, Sugiyama O, Yu D, Lieberman JR.
    Prostate; 2009 Sep 15; 69(13):1422-34. PubMed ID: 19489029
    [Abstract] [Full Text] [Related]

  • 11. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
    Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S.
    Cancer Gene Ther; 2001 Sep 15; 8(9):628-35. PubMed ID: 11593331
    [Abstract] [Full Text] [Related]

  • 12. Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
    Tsui KH, Feng TH, Chung LC, Chao CH, Chang PL, Juang HH.
    Anticancer Res; 2008 Sep 15; 28(4A):1969-76. PubMed ID: 18649734
    [Abstract] [Full Text] [Related]

  • 13. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL, Gardner TA, Miao L, Balian G, Chung LW.
    Cancer Gene Ther; 2004 Feb 15; 11(2):148-55. PubMed ID: 14695756
    [Abstract] [Full Text] [Related]

  • 14. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
    Trofimova I, Dimtchev A, Jung M, Rosenthal D, Smulson M, Dritschilo A, Soldatenkov V.
    Cancer Res; 2002 Dec 01; 62(23):6879-83. PubMed ID: 12460902
    [Abstract] [Full Text] [Related]

  • 15. Decoy androgen-responsive element DNA can inhibit androgen receptor transactivation of the PSA promoter gene.
    Zhang P, Zhang J, Young CY, Kao PC, Chen W, Jiang A, Zhang L, Guo Q.
    Ann Clin Lab Sci; 2005 Dec 01; 35(3):278-84. PubMed ID: 16081584
    [Abstract] [Full Text] [Related]

  • 16. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.
    Culig Z, Stober J, Gast A, Peterziel H, Hobisch A, Radmayr C, Hittmair A, Bartsch G, Cato AC, Klocker H.
    Cancer Detect Prev; 1996 Dec 01; 20(1):68-75. PubMed ID: 8907206
    [Abstract] [Full Text] [Related]

  • 17. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LW.
    Cancer Res; 2001 Aug 15; 61(16):6012-9. PubMed ID: 11507044
    [Abstract] [Full Text] [Related]

  • 18. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
    Shibahara T, Onishi T, Franco OE, Arima K, Nishikawa K, Yanagawa M, Hioki T, Watanabe M, Hirokawa Y, Shiraishi T, Sugimura Y.
    Anticancer Res; 2006 Aug 15; 26(5A):3365-71. PubMed ID: 17094454
    [Abstract] [Full Text] [Related]

  • 19. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A, Fraizer GC, Piantanelli L, Saunders GF.
    Anticancer Res; 2001 Aug 15; 21(1A):1-10. PubMed ID: 11299720
    [Abstract] [Full Text] [Related]

  • 20. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
    Xie X, Zhao X, Liu Y, Zhang J, Matusik RJ, Slawin KM, Spencer DM.
    Cancer Res; 2001 Sep 15; 61(18):6795-804. PubMed ID: 11559553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.